Status:
UNKNOWN
Hepatotoxicity Related to Protein Kinase Inhibitors
Lead Sponsor:
Central South University
Conditions:
Cancer
Eligibility:
All Genders
Brief Summary
Although protein kinase inhibitors (PKIs) have proved effective in treating many cancers, few patients receiving PKIs may experience rare but life-threatening hepatotoxicity such as hepatic failure. T...
Detailed Description
The investigators plan to include FDA approved PKIs from PKIDB, a curated, annotated and updated database of protein kinase inhibitors (https://www.icoa.fr/pkidb/). The search terms of hepatotoxiciti...
Eligibility Criteria
Inclusion
- Case reported in the FAERS database of individual safety case reports at the time of the extraction,
- Patients treated with at least 1 PKIs.
Exclusion
- Chronology not compatible between the PKIs and hepatotoxicities
Key Trial Info
Start Date :
June 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 10 2022
Estimated Enrollment :
600000 Patients enrolled
Trial Details
Trial ID
NCT05430126
Start Date
June 19 2022
End Date
August 10 2022
Last Update
June 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central South University
Changsha, Hunan, China, 410000